Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Net Cash Flow (2016 - 2025)

CytomX Therapeutics' Net Cash Flow history spans 12 years, with the latest figure at -$21.0 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 732.77% year-over-year to -$21.0 million; the TTM value through Dec 2025 reached -$24.9 million, down 218.55%, while the annual FY2025 figure was -$24.9 million, 218.55% down from the prior year.
  • Net Cash Flow reached -$21.0 million in Q4 2025 per CTMX's latest filing, down from -$14.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $137.8 million in Q1 2021 to a low of -$137.3 million in Q1 2023.
  • Average Net Cash Flow over 5 years is -$8.9 million, with a median of -$11.9 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: surged 498.98% in 2024, then tumbled 732.77% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$30.8 million in 2021, then skyrocketed by 420.66% to $98.6 million in 2022, then tumbled by 108.98% to -$8.9 million in 2023, then surged by 71.49% to -$2.5 million in 2024, then crashed by 732.77% to -$21.0 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Net Cash Flow are -$21.0 million (Q4 2025), -$14.9 million (Q3 2025), and $1.4 million (Q2 2025).